证据资料库

中国在医药供应链中的角色

所选公开来源描述行业供应链,其范围与单笔报价可用的设施或服务不同。

所引企业、机构与数据仅提供公开行业背景,不代表与本公司的合作、背书、认证或商业关系。

来源涵盖内容

所选公开来源描述行业供应链,其范围与单笔报价可用的设施或服务不同。

明确范围

这些独立来源不证明与 BLOPEP 存在合作关系,也不证明我们的产品获得认证或某批次获批。详情与局限请查阅原始文件。

来源与核实范围

已报告贸易数据 · S05

Brazil pharmaceutical imports by partner, HS 30, 2025 ↗

WITS / UN Comtrade

来源详情(原文语言)
范围
Brazilian imports of pharmaceutical products, HS chapter 30
文件位置
Reporter Brazil, partner China; trade value 1000 USD
局限
Not peptide-only, not all APIs, and not Bolang sales.
陈述核实日期
2026-09-09
已报告贸易数据 · S06

Pharmaceutical imports from China, HS 30, 2025 ↗

WITS / UN Comtrade

来源详情(原文语言)
范围
Reported pharmaceutical imports from China, HS chapter 30
文件位置
United States and European Union rows; trade value 1000 USD
局限
Do not add EU aggregate to member countries. Not peptide-only trade.
陈述核实日期
2026-09-09
企业披露 · S07

Eli Lilly and Company Form 10-K, fiscal year 2025 ↗

SEC · filing by Eli Lilly and Company

来源详情(原文语言)
范围
Lilly reports reliance on China-based suppliers for portions of its supply chain
文件位置
Manufacturing and supply, p. 21; third-party supply chain risk factors
局限
Does not identify Bolang, peptide purchases from Bolang, partnership, endorsement or certification.
陈述核实日期
2026-09-09
企业披露 · S08

WuXi AppTec expands global manufacturing capacity ↗

WuXi AppTec

来源详情(原文语言)
范围
Corporate statement: >100,000 L at end of 2025; expansion toward 130,000 L
文件位置
SPPS reactor volume paragraph
局限
WuXi AppTec capacity only; target is not installed capacity. Not WuXi Biologics or Bolang.
陈述核实日期
2026-09-09
企业披露 · S11

Notícias: cooperação e presença global ↗

Chemitex

来源详情(原文语言)
范围
Chemitex reports cooperation with Zhejiang Jiuzhou
文件位置
Cooperation announcement and Presença Global em 2025
局限
Self-reported cooperation, not transaction-level customs evidence. Geographic wording was not repeated.
陈述核实日期
2026-09-09

相关阅读